Welcome to our dedicated page for Applied Molecular Transport news (Ticker: AMTI), a resource for investors and traders seeking the latest updates and insights on Applied Molecular Transport stock.
Applied Molecular Transport Inc. (AMTI) is a clinical-stage biopharmaceutical company focused on the development of innovative oral biological therapeutics. Leveraging its proprietary technology platform, AMTI designs novel biologic product candidates in patient-friendly oral dosage forms. Their core expertise lies in mucosal immunology and microbiome-epithelial interfaces, leading to the creation of first-in-class molecules aimed at treating autoimmune, inflammatory, and other grievous diseases, including cancer, metabolic, and hepatologic disorders.
Recent developments highlight AMTI's pursuit of strategic alternatives, with MTS Health Partners, L.P. advising the company. As of June 30, 2023, cash and cash equivalents stood at $22.5 million. The company has undergone significant restructuring, including workforce reductions and the cessation of all research and development activities, reflected in a decrease in R&D expenses from $22.8 million in Q2 2022 to $2.6 million in Q2 2023.
AMTI's most advanced product candidate, AMT-101, has completed four Phase 2 clinical trials. In a strategic move, AMTI has entered a merger agreement with Cyclo Therapeutics, Inc., expected to finalize by the end of 2023. This merger aims to advance Cyclo Therapeutics' pivotal Phase 3 study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1), with the combined company operating under the Cyclo Therapeutics name and trading on Nasdaq as CYTH.
The merger is anticipated to bolster the combined company's cash position, extending the runway into the second half of 2024, crucial for meeting clinical and regulatory milestones. Shawn Cross, CEO of AMTI, will join the Cyclo Therapeutics Board, ensuring continuity and strategic alignment.
Applied Molecular Transport Inc. (Nasdaq: AMTI) will have its CEO, Tahir Mahmood, participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 2:20 p.m. ET. The event will be streamed live on their website, with an archived replay available for 30 days post-event. AMT is a clinical-stage biopharmaceutical company focused on developing oral biologic product candidates aimed at treating autoimmune, inflammatory, and metabolic diseases. Their technology enables precise targeting of therapeutic modalities across the intestinal epithelium.
Applied Molecular Transport Inc. (AMTI) reported positive Phase 2 results for AMT-101, targeting chronic pouchitis, a challenging inflammatory bowel disease. The trial met pre-specified efficacy endpoints, demonstrating a 36.4% stool frequency response in patients. Notably, 22.7% achieved histologic healing. The independent Data Monitoring Committee recommends advancing AMT-101 to Phase 3. AMT-101 shows potential as a best-in-class treatment, addressing significant unmet medical needs in this orphan indication. The company plans to share full results at an upcoming medical conference.
Applied Molecular Transport (AMTI) will disclose top-line results from its Phase 2 FILLMORE trial of AMT-101, aimed at treating chronic pouchitis, on April 25, 2022. The trial focuses on the effectiveness of this GI-selective oral fusion of IL-10. The data will be shared during a premarket conference call at 8:30 a.m. ET. The company, based in South San Francisco, specializes in developing novel oral biologic candidates for autoimmune and inflammatory diseases using its proprietary technology to enhance therapeutic transport across the intestinal barrier.
Applied Molecular Transport Inc. (AMTI) announced new insights regarding its oral biologic products, AMT-101 and AMT-126, published in Tissue Barriers. This research reveals the critical interactions between the cholix carrier and intracellular components that facilitate the transport of these biologics across the intestinal epithelial barrier. The findings have potential implications for treating diseases like ulcerative colitis and rheumatoid arthritis by enhancing targeted drug delivery. The study underscores the unique mechanism of AMT's technology platform, positioning it favorably for future development.
Applied Molecular Transport Inc. (Nasdaq: AMTI) has appointed Charlene Banard to its Board of Directors, enhancing its leadership with her 30+ years of biopharmaceutical experience. Banard will also join the Audit Committee, bringing her expertise in technical operations and strategy. CEO Tahir Mahmood highlighted the significance of her role as AMT advances its pipeline, with key Phase 2 data readouts expected this year.
Banard's previous roles include chief technical officer at Atara Biotherapeutics and head of Technical Operations at Novartis. AMT is focused on developing oral biologic therapeutics for autoimmune diseases.
Applied Molecular Transport Inc. (Nasdaq: AMTI) has appointed Carolyn Finkle as the senior vice president and head of regulatory affairs, a key position in the company's leadership team. With over 30 years of regulatory experience, her role will be crucial as AMT anticipates top-line data from four Phase 2 clinical trials of its oral biologic AMT-101 in 2022. The appointment aligns with AMT's strategy to enhance regulatory interactions as it develops products aimed at major markets in mucosal immunology.
Applied Molecular Transport Inc. (Nasdaq: AMTI) reported its Q4 and 2021 financial results, highlighting anticipated Phase 2 trial readouts for oral AMT-101 in 2022. The company expects key data from four ongoing trials addressing chronic pouchitis and ulcerative colitis, enhancing prospects for AMT-101 and AMT-126. R&D expenses surged to $21.7 million in Q4 2021, raising total expenses for the year to $71.4 million. A net loss of $30.2 million was recorded for Q4, totaling $100.3 million for the year, though total cash resources increased to $159.8 million by year-end.
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 - Applied Molecular Transport Inc. (Nasdaq: AMTI) announced that CEO Tahir Mahmood, Ph.D., will participate in a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 17, 2022, at 1:00 p.m. ET. A live webcast will be available on the company’s Events page, with an archived replay for 30 days post-event. AMT specializes in developing novel oral biologics targeting autoimmune and inflammatory diseases, leveraging its proprietary technology platform for efficient drug delivery.
Applied Molecular Transport Inc. (Nasdaq: AMTI) has announced key leadership changes effective January 27, 2022. John W. Smither has been appointed to the Board of Directors and will serve as Chair of the Audit Committee. Graham K. Cooper will take on the role of Executive Chair, while Helen S. Kim is named Lead Independent Director. CEO Tahir Mahmood emphasized the importance of these appointments as AMT approaches four Phase 2 top-line data readouts for AMT-101, a novel oral biologic currently in development for autoimmune and inflammatory diseases.
Applied Molecular Transport Inc. (Nasdaq: AMTI) announced that Dr. Bittoo Kanwar and Liz Bhatt will participate in a fireside chat at the Virtual Jefferies London Healthcare Conference on November 18, 2021, at 8:00 a.m. GMT. The discussion will focus on AMT's innovative approach to developing oral biologic product candidates targeting autoimmune and metabolic diseases. A recorded version of the chat will be available on AMT's Events page for 30 days post-event. AMT utilizes a proprietary platform for efficient therapeutic transport across the intestinal barrier, setting it apart in the biopharmaceutical landscape.
FAQ
What is the market cap of Applied Molecular Transport (AMTI)?
What is Applied Molecular Transport Inc. (AMTI)?
What are the recent financial highlights for AMTI?
What is AMTI's most advanced product candidate?
What strategic move has AMTI recently made?
When is the AMTI-Cyclo Therapeutics merger expected to close?
What will be the focus of the combined company post-merger?
Who will join the Cyclo Therapeutics Board post-merger?
How will the merger impact the combined company's financial position?
What proprietary technology platform does AMTI use?
Where can I find more information about AMTI?
